Navigation Links
Generex Common Stock Now Quoted on the Over-the-Counter Bulletin Board
Date:11/4/2010

Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinica
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Generex to Participate in Canadian Diabetes Association Conference
2. Generex Reschedules Live Video Webcast
3. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
4. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
5. Generex Provides Clarification for Special Meeting Voting
6. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
7. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
8. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
9. Generex Presents Abstract at EASD Annual Meeting
10. Generex Announces Sales Agreement with Elias Shaker & Company
11. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
(Date:1/14/2014)... , Jan. 14, 2014   NuAire , a manufacturer of ... agreement with Hitachi Koki of Japan ... North America . NuAire will utilize its network ... and Canada to offer assistance in application ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... 26, 2007 /PRNewswire-FirstCall/ --,Replidyne, Inc. today announced ... a novel topical antibiotic that has shown ... including,methicillin-resistant S. aureus (MRSA). The results of ... REP8839 appears safe,well-tolerated and associated with low ...
... in a randomized phase II/III clinical trial,anticipated ... /PRNewswire-FirstCall/ -- Cell,Therapeutics, Inc. (CTI) announced the ... with pixantrone (BBR,2778) resulted in minimal or ... significant cardiac damage.,The studies compared the cardiac ...
Cached Medicine Technology:Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 2Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 3Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 5Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 6
(Date:4/24/2014)... On April 28, the Center for BrainHealth will ... our most pressing brain-related challenges at its inaugural ... Resilience and Regeneration." Featured speakers will include Dr. ... the Center for BrainHealth, U.S. Senator Chuck Grassley ... Doggett, Deputy Assistant Secretary for Policy and Early ...
(Date:4/24/2014)... more than one out of three survivors of ... in The Lancet Respiratory Medicine , and ... rather than mentally. , It is one of ... and functional outcomes of critical care survivors, according ... of Medicine, and it highlights a significant public ...
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... 24, 2014 Pregnant immigrants from Sub-Saharan Africa, ... monitoring during pregnancy, according to new research from ... in the British Journal of Obstetrics and ... eclampsia rates among immigrants and native-born women in ... Denmark, Sweden, Spain (Catalonia and Valencia) and the ...
(Date:4/23/2014)... April 23, 2014 The American Society for Radiation ... Role of Postoperative Radiation Therapy for Endometrial Cancer: ... of adjuvant radiation therapy in the treatment of ... in the May-June 2014 issue of Practical ... journal of ASTRO. The full-length guideline is available ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... are readmitted within a year, study finds , , WEDNESDAY, ... patients discharged from the hospital is readmitted within 30 ... within a year, a new study finds. , The ... problem that researchers believe could be prevented through better ...
... Extreme Physical Performance (EP2), a sport supplement firm, has ... that manufactures a new generation of safe and effective ... human physical performance. Together, they will bring innovative new ... gym goers. TORABOLIC is Indus,s first new novel ingredient ...
... YORK, April 1 Spring may be synonymous ... for Alex Mele of Coram, NY, a 15-year-old baseball player ... a fight to shut out cancer.Mele, a catcher and third ... Junior Varsity Baseball Team, suddenly fell ill last November. ...
... SAN DIEGO, April 1 Gen-Probe (Nasdaq: ... its co-respondents F. Hoffmann-La Roche Ltd. and Roche Molecular ... (now Qiagen) concerning the Company,s supply and purchase agreement ... , Earlier today, a three-member arbitration panel ...
... Touch(TM) hearing aid is smallest receiver-in-canal product availableSALT LAKE ... SNCI ) will celebrate its first receiver-in-canal ("RIC") ... be held in Dallas, Texas, April 2 through 4, ... is the smallest receiver-in-canal product available in the market. ...
... 1 Novavax Inc. (Nasdaq: NVAX) announced ... of 12.5 million shares of Novavax,s common stock at $0.88 per ... of the new strategic alliance between Novavax and Cadila. Novavax intends ... to pay a portion of its 4.75% senior convertible notes due ...
Cached Medicine News:Health News:High Rate of Rehospitalizations Costing Billions 2Health News:High Rate of Rehospitalizations Costing Billions 3Health News:New Sports Supplement Company to Partner with Indus Biotech 2Health News:Blood, Marrow Drive Offers Hope for Baseball Player, 15 2Health News:Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement 2Health News:Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement 3Health News:Sonic Innovations Celebrates Company's First Receiver-In-Canal Hearing Aid 2Health News:Sonic Innovations Celebrates Company's First Receiver-In-Canal Hearing Aid 3Health News:Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals 2
... proven to be a successful alternative ... knee arthroplasty with proper indications. The ... unicompartmental knee system developed to streamline ... latest conservative surgical techniques with the ...
... Knee CR system was designed to ... femoral joint has a recessed, deepened ... advancement of the patella, which has ... The anatomic groove promotes more normal ...
The Biopro Modular TKO implant is among the thinnest bone conserving Posterior Cruciate Ligament sparing knees available. It provides all the benefits of the Biopro TKO implant and gives the option o...
... PowerSuite™ holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
Medicine Products: